our Premium Content: News alerts, weekly reports and conference planners

DRUG:

4SCAR-T

News alerts, weekly reports and conference planners

Company:

SZGIMI

Drug class:

CD20-targeted CAR-T immunotherapy, CD123-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy, CD10-targeted CAR-T immunotherapy, CD38-targeted CAR-T immunotherapy

Related drugs:

‹

anti-CD22 CAR-T therapy (0)

anti-CD22-CAR (0)

CRG-022 (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)

Anti-CD19/CD20/CD22 CAR T-Cells (0)

CAR-20/19-T Cells (0)

CAR-T CD19/CD20/CD22/CD30 (0)

CAR20.19.22 T (0)

CART20 (0)

CBM-C20.1 (0)

CD19/CD20 CAR T-cells (0)

CD20-CART (0)

CD20-CD19 cCAR T cells (0)

autologous TriCAR T (0)

bbT369 (0)

multi-CAR-T cell therapy (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

Autologous CAR-T cells (0)

CART123 (0)

CD123 CAR-T cell therapy (0)

CD123-CAR T cell therapy (0)

EQ (0)

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

IM23 (0)

MB-102 (0)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)

SENL401 (0)

anti-CD123 CAR-T (0)

CAR-T19/CAR-T22 immunotherapy (1)

AUTO1/22 (0)

AUTO3 (0)

Anti-CD22 CAR-T Cells (0)

CART-19/22 (0)

CART22 (0)

CD19 and CD22 targeted prime CAR-T (0)

CD19-CD22 CAR-T (0)

CD19/CD22 CAR T-cells (0)

CD19/CD22 CAR-T cell therapy (0)

CD19/CD22 chimeric antigen receptor T cell (0)

CD19/CD22 dual-target CAR-T (0)

CD19x22 CAR T (0)

CD22-CART (0)

CD22-targeted CAR-T cell therapy (0)

anti-CD19/CD22 CAR-T cells (0)

anti-CD22 CAR T (0)

anti-CD22 CAR-T cell therapy (0)

anti-CD22 CAR-T therapy (0)

anti-CD22-CAR (0)

CRG-022 (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

CART-38 (0)

›

almost4years

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (clinicaltrials.gov)

P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute

almost 4 years ago

Clinical • New P1/2 trial

CD276 (CD276 Molecule)

4SCAR-T

over4years

Multi-4SCAR-T Therapy Targeting Breast Cancer (clinicaltrials.gov)

P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute

over 4 years ago

New P1/2 trial • CAR T-Cell Therapy

HER-2 (Human epidermal growth factor receptor 2) • CD44 (CD44 Molecule)

HER-2 expression • CD44 expression

4SCAR-T

over4years

4SCAR-T Therapy Post CD19-targeted Immunotherapy (clinicaltrials.gov)

P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute

over 4 years ago

New P1/2 trial

CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • MME (Membrane Metalloendopeptidase)

4SCAR-T